
BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering
BioCryst Pharmaceuticals BCRX agrees to sell its European Orladeyo (berotralstat) business to Neopharmed Gentili for up to $264 million. Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary …